CBT 001

Drug Profile

CBT 001

Alternative Names: CBT-001

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Cidara Therapeutics
  • Class Eye disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Recurrent pterygium

Most Recent Events

  • 16 Feb 2017 Preclinical trials in Recurrent pterygium in USA (Ophthalmic) before February 2017
  • 16 Feb 2017 Cloudbreak therapeutics plans a phase II trial for Recurrent pterygium in USA (NCT03049852)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top